The company’s losses widened to £2 million, from £1.1 million a year earlier, and earnings before interest, tax, depreciation and amortisation were £200,000, in line with Diaceitics’ accelerated investment strategy that it announced earlier this year.
“Most encouraging is the positive feedback we continue to receive from our clients as they increasingly use the DXRX platform to support the digital commercialisation of therapies delivered to patients in need worldwide. We remain confident in our proven growth strategy and ability to perform and deliver future growth as we continue to hit our key milestones for the DXRX platform expansion and introduce new products to profile and target suitable patients.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: